Physician-assessed effectiveness and patient-reported outcomes in adult and adolescent atopic dermatitis patients in the Asian subpopulation treated with dupilumab: real-world insights 1 year into the GLOBOSTAD multinational, prospective observational study

Wen-Hung Chung,1 Yoko Kataoka,1 Chia-Yu Chu,2 Shintaro Takeoka,2 Chih-Hung Lee,3,4 Yayoi Tada,5,6 Po-Ju Lai,7 Chih-Hung Lee,8 Hidetoshi Takahashi,8 Akiko Yamagami,9,10 Jiangming Wu11,12,13 Kwinten Bosman12

1Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Osaka Hakubinsu Medical Center, Osaka, Japan; National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University College of Medicine, Taipei, Taiwan; Takeoka Dermatology Clinic, Nagano, Kagawa, Japan; 2Kashinong Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 3Tokyo University School of Medicine, Tokyo, Japan; 4Chung Shan Medical University Hospital, Taichung, Taiwan; 5Takegaki Dermatological Clinic, Hokkaido, Japan; 6First Health University School of Medicine, Aichi, Japan; 7Sanofi, Bridgewater, NJ, USA; 8Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; 9Teikyo University School of Medicine, Tokyo, Japan; 10Fujita Health University School of Medicine, Aichi, Japan; 11Sanofi, Bridgewater, NJ, USA; 12Regeneron Pharmaceuticals Inc. – employee and shareholder. 13Sanofi – employees, may hold stock and/or stock options in the company.

Background

• The objectives of the GLOBOSTAD (NCT03992417) study include an assessment of real-world effectiveness of dupilumab in patients with atopic dermatitis (AD) receiving it as a part of their normal care.

Methods

• This study included patients ≥12 years old with moderate-to-severe AD who initiated dupilumab treatment based on country-specific prescribing criteria.

Objective

• To report real-world long-term effectiveness of dupilumab in treating AD in Asian subpopulations within a year of initiation of treatment.

Results

• In Asian patients with moderate-to-severe AD, the initiation of dupilumab treatment led to early and sustained improvements in signs, symptoms, and quality of life.

Conclusion

• Overall safety was consistent with the known dupilumab safety profile.